The company is spun out of imec, the world-leading R&D and innovation hub in nanoelectronics and digital technologies, and a research collaboration with Johns Hopkins University, the leading US research and medical center.
Our proprietary nano-fluidic processor on a chip and reader require only a small sample volume and no complex instrumentation. The sample moves through the test card using capillary forces alone. Results are delivered to the reader in under 15 minutes, with lab-quality sensitivity and specificity, direct to the patient and clinician.
miDiagnostics is developing an extensive portfolio of tests for screening, diagnosis and monitoring of a wide range of health conditions, including infectious diseases.
Nicolas Vergauwe PhD
Chief Executive Officer
Nicolas joined miDiagnostics as Chief Executive Officer in April 2018. He leads the team at miDiagnostics which is developing and extending the miDiagnostics product portfolio by building on the ground-breaking research of imec and Johns Hopkins University.
Nicolas has extensive experience in the development of innovative diagnostic products, having joined the company from Biocartis, a molecular diagnostics company that has developed a sample-to-result platform for oncology and infectious disease applications. Until March 2018, Nicolas was Vice President, Innovations at Biocartis, where he was responsible for bringing novel technologies and assay concepts to the market. Prior to this, Nicolas was a scientist at Biocartis, joining in January 2012 after obtaining his PhD in Bioscience Engineering at the Katholieke Universiteit Leuven, Belgium.
Chief Financial Officer
Alexander joined miDiagnostics as Chief Financial Officer in September 2019. He brings 8 years’ experience as investment manager and CFO of various companies in capex intensive industries in which he completed numerous acquisitions, equity raises and financings.
Prior to joining miDiagnostics he was CFO of an investment holding company with €300m of assets under management. He started his career as a strategy consultant at McKinsey & Co where he focused on M&A and private equity topics across a wide range of industries and geographies.
Alexander obtained a MSc in Business Engineering from KULeuven and a MSc in Finance from the London School of Economics. He also has a certificate in Molecular Pathology Fundamentals from the American Association of Clinical Chemistry.
Peter Peumans PhD
Peter helped to found miDiagnostics in 2015, having initiated imec’s research program into silicon chip based point-of-care diagnostics. He currently holds the role of CTO Health Technologies at imec and is one of the founding fathers of miDiagnostics.
Prior to this, Peter was a Professor of Electrical Engineering at Stanford University where his work focused on large area electronics, solar energy conversion and biomedical electronics.
Peter holds a PhD in electrical engineering from Princeton University in the US, and a Bachelors and Masters degree in engineering from the Katholieke Universiteit Leuven. He is the recipient of a US National Science Foundation Career Award and a Belgian-American Educational Foundation honorary fellowship.
Mireille Maenhoudt PhD
Mireille joined miDiagnostics as Vice-President R&D in November 2020. She brings experience in innovation and R&D management in nano-electronics and measurement systems technology.
Mireille worked at imec for 17 years where she held different positions in R&D, program and people management in the Silicon process technology division. After imec, she served as Executive Vice-President R&D at Heraeus Electro-Nite, where she led a global team developing automated measurement systems and sensors for the molten metal industry.
Mireille Holds a PhD in Physics from the KU Leuven.
VP Quality & Regulatory Affairs
Ben Chambers joined the miDiagnostics team in February 2019. He is responsible for the development and execution of the Regulatory and Quality Strategies for miDiagnostics and its product platform.
Ben has worked in various operations, regulatory and research roles within the pharmaceutical and medical device industries for over 25 years, with companies such as Merck, Johnson & Johnson Medical, Ethicon, LifeScan, and DePuy.
During his career, Ben has had leadership positions within Project Management, Quality Assurance, Operations, Regulatory Affairs and R&D, leading variety of process improvements, product approvals and launches across Europe, the USA and the Far East.
Ben has a BSc in Biochemistry from the University of Nottingham and a Post Graduate Diploma in Management from the University of Bradford.
Christopher Adams PhD
VP Product Development
Christopher Adams joined miDiagnostics in September 2019. He has extensive experience in translating products from early inception to product launch, particularly within the diagnostics industry.
Before joining miDiagnostics, Christopher served for 7 years as Head of Biotechnology and Innovation at QuantuMDx. Christopher holds a PhD in Physics from the University of Glasgow.
Rudi Pauwels PhD
Rudi Pauwels is a serial entrepreneur in the healthcare sector and chairs the Board of Directors of miDiagnostics.
He was the founder and then CEO of Biocartis until 2017, where he focused on developing a new sample-to-result molecular diagnostic solution. Rudi was co-founder and CEO of Tibotec, co-founder and Chairman of Virco and first chairman of Galapagos, a joint venture between Tibotec and Crucell. He is member of the Investment Committee of Smile Invest and is on the Scientific Advisory Board of imec. Rudi also was a Venture Partner in the Life Science team at Advent Venture Partners from 2007 to 2011. He received several international awards for his scientific and entrepreneurial contributions in the healthcare sector.
Rudi holds a PhD in Pharmaceutical Sciences from KULeuven, Belgium.
Ir. Urbain Vandeurzen PhD
Urbain Vandeurzen is a serial entrepreneur and co-chairs miDiagnostics’ Board. He is also the founder and chairman of Smile Invest, a private equity fund focused on supporting innovative growth companies. He is a chairman or member of the board of a number of technology, industrial and financial services companies.
Previously he was co-founder, Chairman and CEO of LMS, The Engineering Innovation Partner of the Global Top 500 manufacturing companies, which was successfully sold to Siemens in 2012. He was board member at Gimv for 12 years, 5 years of which he served as Chairman. He is honorary chairman of VOKA, the Flemish Employers Organization and Chamber of Commerce.
Since 2012, he has been a member of the board of directors at KU Leuven and became chairman of the KULeuven “Opening the Future” fundraising campaign. He is also chairman of the Strategic Research Center of the Manufacturing Industries, Flanders Make, as well as the Strategic Research Institute on Neurodegenerative Disease, Mission Lucidity.
Michel Akkermans is a serial entrepreneur, private investor, advisor and board member, serving on the boards of public and private companies and private equity funds.
He was co-founder, Chairman and CEO of Clear2Pay, a finance technology company focused on global payment solutions, before it was acquired by FIS in 2014. Before Clear2Pay, Michel was founder, CEO and Chairman of FICS, a fintech company specializing in online banking and compliance reporting. In 1999, FICS merged with Security First Technologies, creating S1 Corporation, where he was appointed Chairman. He also was executive chairman of Data4S, a data analytics specialist, focusing on anti-money laundering applications.
Michel holds a Masters in electronic engineering and computer sciences and a degree in economics and finance from the University of Leuven, Belgium. More information on www.pamica.be
Marc Coucke MBA
Marc Coucke is a serial entrepreneur and founder of Alychlo NV, which invests in funds and fast-growing Belgian enterprises.
Marc founded Omega Pharma in 1987 and developed the company into a leading pan-European OTC health and personal care business, Perrigo acquired Omega Pharma in 2015.
Marc graduated as a Qualified Pharmacist from the State University of Ghent, Belgium, and holds an MBA from the Vlerick Business School, Ghent, Belgium, in 2002 he was awarded the EY Flemish Entrepreneur of the Year award.
Pieter Bourgeois MBA
Pieter Bourgeois is an Investment Manager at Alychlo NV, the investment firm of Belgian entrepreneur Marc Coucke.
Prior to this, Pieter worked in a variety of financial roles focusing on M&A and strategic projects, gaining business acumen in a variety of sectors and different sizes of companies.
He holds a Masters Degree in Industrial Engineering and is an MBA from the Solvay Brussels School of Economics & Management.
Peter Collins is currently Chief Business Officer at Inivata. Peter brings over 30 years of experience working in the biopharmaceutical sector, having held senior leadership positions in several molecular diagnostics companies, most recently at Guardant Health.
Peter has also served as Chief Business Officer of Yourgene Health, where he led all aspects of commercialization and business development. Prior to this, Peter was Vice President, Head of Diagnostics at GSK – where he was responsible for the companion diagnostics assets and pipeline across all therapeutic areas, particularly oncology – and VP, Pharma Business Development at QIAGEN. Peter was also a co-founder and board member of Epemed, a European not for profit organization bringing together global forces in personalized medicine.
Peter holds a BSc in Biological Sciences from Plymouth University.
Stuart C. Ray, MD, FACP, FIDSA
Stuart C. Ray serves as Vice Chair of Medicine for Data Integrity and Analytics and is a Professor of Medicine in the Division of Infectious Diseases, with a secondary appointment in Oncology, all within the Johns Hopkins School of Medicine.
He co-chairs research for the Johns Hopkins Medicine (JHM) Data Trust Council, is an Associate Director of JHM inHealth, and directs a virology laboratory where he studies the interplay of viral evolution and human immunology. He is a faculty member of the Graduate Immunology program, the Graduate Pharmacology program, and of the Janeway Firm of the Osler Medical Service. Stuart is an Associate Editor of the Journal of Clinical Investigation.
He received his MD from Vanderbilt University School of Medicine in 1990 and did all of his clinical training at Johns Hopkins.
Luc Van den hove PhD
Luc Van den hove is President and Chief Executive Officer (CEO) of imec, a role he has held since 2009. Before this, he was Executive Vice President and Chief Operating Officer at imec.
Under his leadership, imec has grown to an organization with a staff of around 4,000 people, operating with an annual budget of around €640m (2019) and with offices in Belgium, the Netherlands, US, Japan, Taiwan, China and India. Luc joined imec in 1984.
Luc is also professor of Electrical Engineering at the University of Leuven and a member of the Technology Strategy Committee of ASML.
He received his PhD in Electrical Engineering from the University of Leuven, Belgium. He has authored or co-authored more than 150 publications and conference contributions.
As Managing Partner of VVGB Advocaten-Avocats, Peter Verhaeghe represents major European, American and Asian multinationals, medium-size enterprises and start-ups in all sectors of the economy.
He has significant corporate, corporate finance and tax experience advising clients active in the life sciences, pharmaceutical, hi-tech and assisting and consumer products sector throughout Europe.
Peter has held a wide range of board positions. He is currently Chairman of the Board of argenx SE (the Netherlands), a Euronext and NASDAQ listed company, a member of the Board of Directors of Participatiemaatschappij Vlaanderen (PMV) (Belgium), Chairman of the Board of Directors of Haretis SA (Luxembourg) and Chairman of the Limited Partners and of the advisory committee of Bioqube Factory Fund I.
Peter received his J.D. from KULeuven and his Masters Degree in Law from Harvard Law School.
miDiagnostics’ nanoFluidic Processor technology was initially developed by imec, the world-leading R&D and innovation hub in nanoelectronics and digital technologies, together with the expertise of Johns Hopkins University, the leading US research and medical center. Strategic partnerships will continue to be at the heart of our business model.
In addition, miDiagnostics is collaborating with NASA, through its relationship with imec, having been selected to test miDiagnostics’ reader and CBC technology on parabolic test flights that simulate low-gravity environments.
miDiagnostics has also joined US technology company NVIDIA’s Inception program for advanced machine learning implementations.
Partner with us. Please get in touch to explore business, research and commercial opportunities.
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention”
“When it comes to making diagnostic decisions, it’s time to stop focusing on firefighting, it’s time to start investing in smoke detectors”